Vaxart, Inc. (VXRT)
| Market Cap | 138.74M +30.0% |
| Revenue (ttm) | 255.61M +439.3% |
| Net Income | 37.10M |
| EPS | 0.16 |
| Shares Out | 241.29M |
| PE Ratio | 3.64 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 117,697 |
| Open | 0.5700 |
| Previous Close | 0.5600 |
| Day's Range | 0.5501 - 0.5900 |
| 52-Week Range | 0.2606 - 0.8449 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+417.24%) |
| Earnings Date | Aug 6, 2026 |
About Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for VXRT stock is "Strong Buy." The 12-month stock price target is $3.00, which is an increase of 417.24% from the latest price.
News
Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
Urges Stockholders to Vote “FOR” ALL Six of Vaxart's Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., ...
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 16, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprieta...
Vaxart to Participate in BTIG Infectious Disease Day 2026
SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprieta...
Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
Mails Letter to Shareholders Detailing Strength of the Board's Nominees and Momentum in Advancing Vaxart's Value Creation Strategy Reinforces that the Dissident's Nominees Have No Relevant Biotechnolo...
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 4, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders
Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 21, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 20, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 20, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to V...
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 19, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 19, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Proxy statement: Proxy filing
Vaxart filed a proxy statement on May 19, 2026, providing details for shareholder voting and corporate governance matters.
Vaxart Slides: Corporate presentation
Vaxart has posted slides in relation to its latest quarterly earnings report, which was published on May 19, 2026.
Vaxart Registration statement: Registration filing
Vaxart filed a registration statement on May 18, 2026, providing details about a securities offering with the SEC.
Vaxart Earnings Call Transcript: Q1 2026
Q1 saw strong revenue growth and positive net income, driven by BARDA contracts and cost controls. Key clinical milestones for COVID-19 and norovirus programs are pending, with cash runway into Q2 2027 and flexible capital options in place.
Vaxart Earnings release: Q1 2026
Vaxart released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.